| 查看: 1484 | 回复: 17 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
开发一种新药的惊人花费（The truly staggering cost of inventing new drugs）
|
|||
|
原文链接：http://bioluminor.biomart.cn/news/2770272.htm During the Super Bowl, a representative of the pharmaceutical company Eli Lilly posted the on the company’s corporate blog that the average cost of bringing a new drug to market is $1.3 billion, a price that would buy 371 Super Bowl ads, 16 million official NFL footballs, two pro football stadiums, pay of almost all NFL football players, and every seat in every NFL stadium for six weeks in a row. This is, of course, ludicrous. The average drug developed by a major pharmaceutical company costs at least $4 billion, and it can be as much as $11 billion. The drug industry has been tossing around the $1 billion number for years. It is based largely on a study (supported by drug companies) by Joseph DiMasi of Tufts University. It’s a nice number for the pharmaceutical industry, because it seems to justify the idea that medicines should be pricey (and increasingly, they can be very pricey, costing tens of thousands of dollars per patient per year) without making it seem that inventing new medicines is so expensive an endeavor as to be ultimately futile. But as Bernard Munos of the InnoThink Center for Research In Biomedical Innovation has noted, just adjusting that estimate for current failure rates results in an estimate of $4 billion in research dollars spent for every drug that is approved. But Munos showed me another figure, where he divided each drug company’s R&D budget by the average number of drugs approved. This was far more dramatic. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. Wanting to make this even more rigorous, Forbes (that would be Scott DeCarlo and me) took Munos’ count of drug approvals for the major pharmas and combined it with their research and development spending as reported in annual earnings filings going back fifteen years, pulled from a Thomson Reuters database using FactSet. We adjusted all the figures for inflation. Using both drug approvals and research budgets since 1997 keeps the estimates being skewed by short-term periods when R&D budgets or drug approvals changed dramatically. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. |
回复此楼» 猜你喜欢
胰岛素的实验室表达
已经有0人回复
-
胰岛素的实验室表达
已经有1人回复
-
药物学论文润色/翻译怎么收费?
已经有152人回复
-
胰岛素的实验室表达
已经有0人回复
-
胰岛素的实验室表达
已经有0人回复
-
求助电子版：晶型药物研发理论与应用
已经有0人回复
-
这个自发加氧反应的机理是什么？
已经有7人回复
-
北京大学药学院诚招药物化学/有机化学方向博士后
已经有6人回复
-
2027药学博士申请
已经有1人回复
-
文献求助
已经有0人回复
» 抢金币啦！回帖就可以得到:
-
开心就散金
+5/1815
-
面上中了，散金币。
+5/1440
-
云南大学丁军桥团队2027年博士招生
+1/945
-
八年奋战，面上中了，同时一个读了8年的博士（中途接手）答辩通过了，都是涉险过关
+2/344
-
原子层沉积（ALD）磁控溅射PECVD等微纳代工服务：18817872921
+1/91
-
东南大学能源与环境学院-林日琛教授课题组-27级博士招生
+1/86
-
征友避雷上海【荀玄武】
+1/82
-
中南大学化学化工学院喻桂朋教授团队诚聘博士后（复合材料方向）
+1/37
-
深圳大学刘翼振课题组诚聘博士后（CRISPR分子诊断）
+1/36
-
中南大学化学化工学院喻桂朋教授团队诚聘博士后（复合材料方向）
+1/20
-
四川大学高分子学院、空天学院招收研究助理
+1/18
-
中南大学化学化工学院喻桂朋教授团队诚聘博士后（复合材料方向）
+1/17
-
【科研诚信】武汉轻工大学何江玲3篇论文：涉嫌抄袭、成组数据重复、制造虚假显著
+1/17
-
中国科学院 理化技术研究所 招 动力工程及工程热物理 相近的保送硕士 博士
+1/12
-
湖南大学张旺课题组招收推免硕士
+1/11
-
湖南大学张旺课题组招收研究助理
+1/11
-
中国科学院广州生物医药与健康研究院课题组招收博士研究生1名（2027年9月入学）
+1/4
-
项目助理招聘启事
+1/2
-
课题快结题了才发现没东西可申请专利？四个维度帮你挖一挖
+1/2
-
香港大学智能制造实验室招收27年春秋季入学全奖博士和硕士研究生
+1/1
10楼2015-09-01 08:19:15
7楼2015-08-31 16:02:44
9楼2015-09-01 08:14:29
11楼2015-09-14 11:50:36
投票:
